AU2002212959A1 - Cycloalkylfluorosulfonamide derivatives - Google Patents

Cycloalkylfluorosulfonamide derivatives

Info

Publication number
AU2002212959A1
AU2002212959A1 AU2002212959A AU1295902A AU2002212959A1 AU 2002212959 A1 AU2002212959 A1 AU 2002212959A1 AU 2002212959 A AU2002212959 A AU 2002212959A AU 1295902 A AU1295902 A AU 1295902A AU 2002212959 A1 AU2002212959 A1 AU 2002212959A1
Authority
AU
Australia
Prior art keywords
cycloalkylfluorosulfonamide
derivatives
cycloalkylfluorosulfonamide derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002212959A
Other languages
English (en)
Inventor
Buddy Eugene Cantrell
Winton Dennis Jones
Timothy Alan Shepherd
Hamideh Zarrinmayeh
Dennis Michael Zimmerman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2002212959A1 publication Critical patent/AU2002212959A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C307/04—Diamides of sulfuric acids
    • C07C307/08—Diamides of sulfuric acids having nitrogen atoms of the sulfamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/07—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2002212959A 2000-10-13 2001-09-28 Cycloalkylfluorosulfonamide derivatives Abandoned AU2002212959A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US24035100P 2000-10-13 2000-10-13
US60240351 2000-10-13
US29451401P 2001-05-30 2001-05-30
US60294514 2001-05-30
PCT/US2001/027740 WO2002032858A1 (fr) 2000-10-13 2001-09-28 Derives de cycloalkylfluorosulfonamide

Publications (1)

Publication Number Publication Date
AU2002212959A1 true AU2002212959A1 (en) 2002-04-29

Family

ID=26933348

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002212959A Abandoned AU2002212959A1 (en) 2000-10-13 2001-09-28 Cycloalkylfluorosulfonamide derivatives

Country Status (6)

Country Link
US (1) US6900353B2 (fr)
EP (1) EP1334087A1 (fr)
JP (1) JP2004511540A (fr)
AU (1) AU2002212959A1 (fr)
CA (1) CA2421597A1 (fr)
WO (1) WO2002032858A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9702194D0 (en) 1997-02-04 1997-03-26 Lilly Co Eli Sulphonide derivatives
US6639107B1 (en) 1999-12-08 2003-10-28 Eli Lilly And Company Cyclopentyl sulfonamide derivatives
JP2004530708A (ja) * 2001-06-05 2004-10-07 イーライ・リリー・アンド・カンパニー スルホンアミド誘導体
EP1786769A1 (fr) * 2004-08-09 2007-05-23 Glaxo Group Limited Composés potentialisateurs de récepteur de glutamate et utilisations de ceux-ci en médecine
DE602006003661D1 (de) 2005-06-06 2008-12-24 Lilly Co Eli Ampa-rezeptoren-verstärker
JP5014334B2 (ja) * 2005-10-06 2012-08-29 イーライ リリー アンド カンパニー Ａｍｐａ受容体増強剤
AU2008259841B2 (en) * 2007-05-31 2015-02-05 Sunovion Pharmaceuticals Inc. Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors
EP2361246A1 (fr) * 2008-10-02 2011-08-31 Pfizer Inc. Oxopipéridinylsulfamides et pyranylsulfamides utilisables en tant que potentialisateurs des récepteurs ampa
US20110178165A1 (en) * 2008-10-08 2011-07-21 Pfizer Inc. Tetrahydrofuranyl sulfonamides and pharmaceutical compositions thereof
EP2544688B1 (fr) 2010-03-02 2016-09-07 President and Fellows of Harvard College Procédés et compositions pour le traitement du syndrome d'angelman
US8911543B2 (en) * 2012-12-18 2014-12-16 Xerox Corporation Phenylcyclohexanol derivatives as wax modifiers and gelators
BR112015014303A2 (pt) * 2012-12-19 2017-07-11 Basf Se compostos de fórmula i, processo para a preparação dos compostos de fórmula i, composições agroquímicas, utilização de um composto de fórmula i, método para o combate dos fungos, semente e compostos intermediários xx3
TWI602803B (zh) * 2013-03-29 2017-10-21 第一三共股份有限公司 光學活性二胺衍生物之製造方法
CN105579575A (zh) 2013-06-13 2016-05-11 维罗技术有限责任公司 用于治疗代谢失调的组合物和方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19525137C2 (de) * 1995-07-11 2003-02-27 Gruenenthal Gmbh 6-Dimethylaminomethyl-1-phenyl-cyclohexanverbin -dungen als Zwischenprodukte zur Herstellung pharmazeutischer Wirkstoffe
GB9702194D0 (en) * 1997-02-04 1997-03-26 Lilly Co Eli Sulphonide derivatives
PE20000944A1 (es) * 1998-07-31 2000-09-20 Lilly Co Eli Derivados de sulfonamida
EP1246797B1 (fr) * 1999-12-08 2008-07-23 Eli Lilly And Company Derives de sulfonamide de cyclopentyle

Also Published As

Publication number Publication date
US20040067984A1 (en) 2004-04-08
WO2002032858A1 (fr) 2002-04-25
CA2421597A1 (fr) 2002-04-25
JP2004511540A (ja) 2004-04-15
EP1334087A1 (fr) 2003-08-13
US6900353B2 (en) 2005-05-31

Similar Documents

Publication Publication Date Title
AU2001280099A1 (en) 4-acylaminopyrazole derivatives
AU2001230584A1 (en) 1h-imidazopyridine derivatives
AU2001262847A1 (en) Language-understanding
AU2001230537A1 (en) Pyridoxazine derivatives
AU2001254546A1 (en) Aminopiperidines
AU2000267458A1 (en) Hypercomputer
AU2001281802A1 (en) 6-phenylpyrrolopyrimidinedione derivatives
AU2001239310A1 (en) Decahydro-isoquinolines
AU2001220246A1 (en) Neckphone
AU2001278790A1 (en) 1h-imidazopyridine derivatives
AU2001258349A1 (en) Bisacylguanidine
AU2002213978A1 (en) Substituted C-cyclohexylmethylamine derivatives
AU2002212301A1 (en) Diazacycloalkanedione derivatives
AU5256301A (en) Froindazole derivative
AU2002212959A1 (en) Cycloalkylfluorosulfonamide derivatives
AU2001258924A1 (en) Microsatellite-aflp
AU2002215212A1 (en) 1-methylcarbapenem derivatives
AU2001289937A1 (en) Substituted 1-aminobutan-3-ol derivatives
AU2001254661A1 (en) Aminosulfonylbiphenyl derivatives
AU2001230565A1 (en) Perfluoroisopropylbenzene derivatives
AU2001234313A1 (en) Novel phenylheteroalkylamine derivatives
AU2001242772A1 (en) 3-substituted-4-pyrimidone derivatives
AU2001246864A1 (en) Hypotensors
AU2002221632A1 (en) 5-amino-1-pentene-3-ol substituted derivatives
AU2002212263A1 (en) Substituted 5-amino-1-pentene-3-ol derivatives